STAT+: Cancer medicines remain in short supply across the U.S., survey finds

A nationwide shortage of cancer medicines continues to plague leading cancer treatment centers in the United States, according to a new survey conducted by the National Comprehensive Cancer Network. Thirty-four top cancer treatment centers participated in the survey, revealing the extent of the supply issues. Every center reported experiencing a shortage of at least one medication, with over 20% currently facing shortages of five or more distinct drugs.

Despite these challenges, 61% of the centers stated they are still able to treat patients, albeit by employing strategies to minimize waste and limit the use of existing stock. These workarounds include administering the minimum suggested dosing to stretch the limited supply. However, 66% of the centers reported that these shortages are causing delays in treatment, as they must once again obtain prior authorization from insurers. This secondary step adds an extra layer of complexity to an already challenging situation.